Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration.

TitleGenetic and clinical features of progranulin-associated frontotemporal lobar degeneration.
Publication TypeJournal Article
Year of Publication2011
AuthorsChen-Plotkin AS, Martinez-Lage M, Sleiman PMA, Hu W, Greene R, Wood EMcCarty, Bing S, Grossman M, Schellenberg GD, Hatanpaa KJ, Weiner MF, White CL, Brooks WS, Halliday GM, Kril JJ, Gearing M, Beach TG, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Pickering-Brown SM, Snowden J, van Swieten JC, Heutink P, Seelaar H, Murrell JR, Ghetti B, Spina S, Grafman J, Kaye JA, Woltjer RL, Mesulam M, Bigio E, Lladó A, Miller BL, Alzualde A, Moreno F, Rohrer JD, Mackenzie IRA, Feldman HH, Hamilton RL, Cruts M, Engelborghs S, De Deyn PP, Van Broeckhoven C, Bird TD, Cairns NJ, Goate A, Frosch MP, Riederer PF, Bogdanovic N, M Y Lee V, Trojanowski JQ, Van Deerlin VM
JournalArch Neurol
Volume68
Issue4
Pagination488-97
Date Published2011 Apr
ISSN1538-3687
KeywordsAged, Female, Frontotemporal Lobar Degeneration, Genetic Markers, Humans, Intercellular Signaling Peptides and Proteins, Male, Middle Aged, Mutation, Parkinsonian Disorders, Progranulins, Protein Precursors
Abstract

OBJECTIVE: To assess the relative frequency of unique mutations and their associated characteristics in 97 individuals with mutations in progranulin (GRN), an important cause of frontotemporal lobar degeneration (FTLD).

PARTICIPANTS AND DESIGN: A 46-site International Frontotemporal Lobar Degeneration Collaboration was formed to collect cases of FTLD with TAR DNA-binding protein of 43-kDa (TDP-43)-positive inclusions (FTLD-TDP). We identified 97 individuals with FTLD-TDP with pathogenic GRN mutations (GRN+ FTLD-TDP), assessed their genetic and clinical characteristics, and compared them with 453 patients with FTLD-TDP in which GRN mutations were excluded (GRN- FTLD-TDP). No patients were known to be related. Neuropathologic characteristics were confirmed as FTLD-TDP in 79 of the 97 GRN+ FTLD-TDP cases and all of the GRN- FTLD-TDP cases.

RESULTS: Age at onset of FTLD was younger in patients with GRN+ FTLD-TDP vs GRN- FTLD-TDP (median, 58.0 vs 61.0 years; P < .001), as was age at death (median, 65.5 vs 69.0 years; P < .001). Concomitant motor neuron disease was much less common in GRN+ FTLD-TDP vs GRN- FTLD-TDP (5.4% vs 26.3%; P < .001). Fifty different GRN mutations were observed, including 2 novel mutations: c.139delG (p.D47TfsX7) and c.378C>A (p.C126X). The 2 most common GRN mutations were c.1477C>T (p.R493X, found in 18 patients, representing 18.6% of GRN cases) and c.26C>A (p.A9D, found in 6 patients, representing 6.2% of cases). Patients with the c.1477C>T mutation shared a haplotype on chromosome 17; clinically, they resembled patients with other GRN mutations. Patients with the c.26C>A mutation appeared to have a younger age at onset of FTLD and at death and more parkinsonian features than those with other GRN mutations.

CONCLUSION: GRN+ FTLD-TDP differs in key features from GRN- FTLD-TDP.

DOI10.1001/archneurol.2011.53
Alternate JournalArch. Neurol.
PubMed ID21482928
PubMed Central IDPMC3160280
Grant ListAG19610 / AG / NIA NIH HHS / United States
AG08671 / AG / NIA NIH HHS / United States
P50 NS053488 / NS / NINDS NIH HHS / United States
AG005136 / AG / NIA NIH HHS / United States
NS53488 / NS / NINDS NIH HHS / United States
AG05134 / AG / NIA NIH HHS / United States
NS044233 / NS / NINDS NIH HHS / United States
AG03949 / AG / NIA NIH HHS / United States
P30 AG013854 / AG / NIA NIH HHS / United States
R01 NS044266 / NS / NINDS NIH HHS / United States
75480 / CAPMC / CIHR / Canada
AG10129 / AG / NIA NIH HHS / United States
P30 AG010124 / AG / NIA NIH HHS / United States
K08 AG033101-05 / AG / NIA NIH HHS / United States
089701 / WT_ / Wellcome Trust / United Kingdom
P30 AG028377 / AG / NIA NIH HHS / United States
P50 AG008671 / AG / NIA NIH HHS / United States
AG05146 / AG / NIA NIH HHS / United States
R01 AG015116 / AG / NIA NIH HHS / United States
P50 AG005142 / AG / NIA NIH HHS / United States
AG16573 / AG / NIA NIH HHS / United States
AG05138 / AG / NIA NIH HHS / United States
AG10124 / AG / NIA NIH HHS / United States
P50 AG005131 / AG / NIA NIH HHS / United States
P30 AG010133 / AG / NIA NIH HHS / United States
AG005681 / AG / NIA NIH HHS / United States
NS44266 / NS / NINDS NIH HHS / United States
P50 AG016574 / AG / NIA NIH HHS / United States
P50 AG005146 / AG / NIA NIH HHS / United States
P01 AG017586 / AG / NIA NIH HHS / United States
P30 AG062421 / AG / NIA NIH HHS / United States
NS15655 / NS / NINDS NIH HHS / United States
AG15116 / AG / NIA NIH HHS / United States
NS065782 / NS / NINDS NIH HHS / United States
AG12300 / AG / NIA NIH HHS / United States
P50 AG008702 / AG / NIA NIH HHS / United States
AG03991 / AG / NIA NIH HHS / United States
P01 AG003991 / AG / NIA NIH HHS / United States
AG005131 / AG / NIA NIH HHS / United States
P50 AG005681 / AG / NIA NIH HHS / United States
P30 AG013846 / AG / NIA NIH HHS / United States
AG16570 / AG / NIA NIH HHS / United States
UL1 RR025741 / RR / NCRR NIH HHS / United States
K08 AG033101-01 / AG / NIA NIH HHS / United States
P50 AG005136 / AG / NIA NIH HHS / United States
P30 AG012300 / AG / NIA NIH HHS / United States
NS038372 / NS / NINDS NIH HHS / United States
AG13846 / AG / NIA NIH HHS / United States
P50 AG016573 / AG / NIA NIH HHS / United States
AG02219 / AG / NIA NIH HHS / United States
P01 AG019724 / AG / NIA NIH HHS / United States
P50 AG016570 / AG / NIA NIH HHS / United States
P50 AG005134 / AG / NIA NIH HHS / United States
P30 AG008017 / AG / NIA NIH HHS / United States
P30 AG010161 / AG / NIA NIH HHS / United States
P01 NS015655 / NS / NINDS NIH HHS / United States
P50 AG005134-28 / AG / NIA NIH HHS / United States
R01 AG018440 / AG / NIA NIH HHS / United States
AG05133 / AG / NIA NIH HHS / United States
G0701441 / MRC_ / Medical Research Council / United Kingdom
AG008017 / AG / NIA NIH HHS / United States
AG025688 / AG / NIA NIH HHS / United States
P50 AG025688 / AG / NIA NIH HHS / United States
K08 AG033101-02 / AG / NIA NIH HHS / United States
AG17586 / AG / NIA NIH HHS / United States
R37 AG018440 / AG / NIA NIH HHS / United States
AG019724 / AG / NIA NIH HHS / United States
P50 AG005133 / AG / NIA NIH HHS / United States
K08 AG033101-03 / AG / NIA NIH HHS / United States
AG010133 / AG / NIA NIH HHS / United States
P01 AG002219 / AG / NIA NIH HHS / United States
P50 NS038372 / NS / NINDS NIH HHS / United States
AG033101 / AG / NIA NIH HHS / United States
/ ImNIH / Intramural NIH HHS / United States
P50 AG005138 / AG / NIA NIH HHS / United States
AG18440 / AG / NIA NIH HHS / United States
K08 AG033101 / AG / NIA NIH HHS / United States
AG16582 / AG / NIA NIH HHS / United States
R01 NS065782 / NS / NINDS NIH HHS / United States
AG10161 / AG / NIA NIH HHS / United States
AG13854 / AG / NIA NIH HHS / United States
P01 NS044233 / NS / NINDS NIH HHS / United States
AG08702 / AG / NIA NIH HHS / United States
P01 AG003949 / AG / NIA NIH HHS / United States
K08 AG033101-04 / AG / NIA NIH HHS / United States
P30 AG010129 / AG / NIA NIH HHS / United States
P30 AG019610 / AG / NIA NIH HHS / United States
P50 AG016582 / AG / NIA NIH HHS / United States
AG16574 / AG / NIA NIH HHS / United States
AG010129 / AG / NIA NIH HHS / United States
AG05142 / AG / NIA NIH HHS / United States
AG028377 / AG / NIA NIH HHS / United States